MCP to Produce Clinical Batches of Innovative Cardiac Drug

MCP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug

PARSIPPANY, NJ July 25, 2011 — MCP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.

Stuart Hinchen, President and CEO of MCP stated, “We are pleased that MCP was chosen to produce clinical batches for this important customer. Our cGMP compliance record, coupled with an experienced staff, gives us an advantage in meeting customer needs throughout a product’s life cycle, starting with clinical batch production.” “We know that customers want to seamlessly transition from clinical batch production to product launch and then commercialization.

MCP has the right scale and experience to meet customer needs across the product life cycle.” Hinchen also noted, “During the last seven months, we successfully completed FDA and EMA audits and entered agreements with five new customers. These agreements are examples of how our approach to continuing investment allows us to focus on customer needs, which results in an internal infrastructure that supports ongoing sustainable growth.” MCP’s Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.

The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases

04/17/13

MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials

Webpage | PDF Format

12/31/12

MCP Pharmaceuticals Acquired By Warburg Pincus

Webpage | PDF Format

09/19/12

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

Webpage | PDF Format

06/07/12

MCP Pharmaceuticals Launches Generic Division